| . | . | . | . | . | P value . | |
|---|---|---|---|---|---|---|
| . | . | All children (N = 101) . | Female (N = 40) . | Male (N = 61) . | Mann-Whitney . | T-test . |
| Baseline | N | |||||
| Age (years) | 101 | 6.2 (1.7) | 5.8 (1.3) | 6.5 (1.8) | 0.06 | |
| Weight (SDS) | 101 | -3.2 (1.0) | -3.2 (1.0) | -3.1 (1.1) | 0.30 | |
| Height (SDS) | 101 | -3.4 (0.8) | -3.5 (0.9) | -3.4 (0.7) | 0.27 | |
| Bioactive IGF-I (µg/L) | 94 | 1.6 (0.7) | 1.8 (0.7) | 1.5 (0.6) | 0.03 | |
| Bioactive IGF-I (SDS) | 94 | -1.2 (1.8) | -0.5 (1.6) | -1.6 (1.8) | 0.005 | |
| IGF-I (ng/mL) | 95 | 81.9 (62.1–111.0) | 91.5 (65.0–118.8) | 79.0 (57.2–110.0) | 0.25 | |
| IGF-I (SDS) | 95 | -1.2 (1.2) | -1.2 (1.1) | -1.1 (1.3) | 0.87 | |
| IGFBP-3 (ng/mL) | 95 | 2870 (2380–3475) | 2870 (2580–3560) | 2780 (2235–3467) | 0.23 | |
| IGFBP-3 (SDS) | 95 | -0.92 (-1.5 to -0.01) | -0.92 (-1.37-0.12) | -0.93 (-1.73 to -0.04) | 0.53 | |
| IGFBP-1 (ng/mL) | 95 | 239 (174–320) | 258 (179–350) | 233 (171–294) | 0.27 | |
| After 1 year of GH therapy | ||||||
| Age (years) | 99 | 7.3 (1.6) | 6.9 (1.4) | 7.5 (1.7) | 0.10 | |
| Weight (SDS) | 96 | -2.2 (1.0) | -2.2 (0.9) | -2.1 (1.2) | 0.70 | |
| Height (SDS) | 99 | -2.4 (0.8) | -2.5 (0.9) | -2.4 (0.8) | 0.58 | |
| Bioactive IGF-I (µg/L) 1 year | 94 | 2.9 (0.9) | 3.0 (0.9) | 2.9 (0.9) | 0.60 | |
| Bioactive IGF-I (SDS) 1 year | 94 | 1.1 (1.4) | 1.1 (1.0) | 1.1 (1.6) | 0.99 | |
| IGF-I (ng/mL) | 95 | 312.0 (225.0–394.0) | 338.0 (282.8–453.5) | 308.0 (217.0–359.5) | 0.05 | |
| IGF-I (SDS) | 95 | 2.8 (1.5) | 2.9 (1.5) | 2.8 (1.5) | 0.67 | |
| IGFBP-3 (ng/mL) | 95 | 4555 (4055–5082) | 4600 (4207–5275) | 4475 (3975–5000) | 0.13 | |
| IGFBP-3 (SDS) | 95 | 1.25 (0.65–1.86) | 1.17 (0.79–1.94) | 1.30 (0.62–1.86) | 0.77 | |
| IGFBP-1 (ng/mL) | 95 | 165 (134–220) | 173 (138–216) | 160 (132–234) | 0.83 | |
| . | . | . | . | . | P value . | |
|---|---|---|---|---|---|---|
| . | . | All children (N = 101) . | Female (N = 40) . | Male (N = 61) . | Mann-Whitney . | T-test . |
| Baseline | N | |||||
| Age (years) | 101 | 6.2 (1.7) | 5.8 (1.3) | 6.5 (1.8) | 0.06 | |
| Weight (SDS) | 101 | -3.2 (1.0) | -3.2 (1.0) | -3.1 (1.1) | 0.30 | |
| Height (SDS) | 101 | -3.4 (0.8) | -3.5 (0.9) | -3.4 (0.7) | 0.27 | |
| Bioactive IGF-I (µg/L) | 94 | 1.6 (0.7) | 1.8 (0.7) | 1.5 (0.6) | 0.03 | |
| Bioactive IGF-I (SDS) | 94 | -1.2 (1.8) | -0.5 (1.6) | -1.6 (1.8) | 0.005 | |
| IGF-I (ng/mL) | 95 | 81.9 (62.1–111.0) | 91.5 (65.0–118.8) | 79.0 (57.2–110.0) | 0.25 | |
| IGF-I (SDS) | 95 | -1.2 (1.2) | -1.2 (1.1) | -1.1 (1.3) | 0.87 | |
| IGFBP-3 (ng/mL) | 95 | 2870 (2380–3475) | 2870 (2580–3560) | 2780 (2235–3467) | 0.23 | |
| IGFBP-3 (SDS) | 95 | -0.92 (-1.5 to -0.01) | -0.92 (-1.37-0.12) | -0.93 (-1.73 to -0.04) | 0.53 | |
| IGFBP-1 (ng/mL) | 95 | 239 (174–320) | 258 (179–350) | 233 (171–294) | 0.27 | |
| After 1 year of GH therapy | ||||||
| Age (years) | 99 | 7.3 (1.6) | 6.9 (1.4) | 7.5 (1.7) | 0.10 | |
| Weight (SDS) | 96 | -2.2 (1.0) | -2.2 (0.9) | -2.1 (1.2) | 0.70 | |
| Height (SDS) | 99 | -2.4 (0.8) | -2.5 (0.9) | -2.4 (0.8) | 0.58 | |
| Bioactive IGF-I (µg/L) 1 year | 94 | 2.9 (0.9) | 3.0 (0.9) | 2.9 (0.9) | 0.60 | |
| Bioactive IGF-I (SDS) 1 year | 94 | 1.1 (1.4) | 1.1 (1.0) | 1.1 (1.6) | 0.99 | |
| IGF-I (ng/mL) | 95 | 312.0 (225.0–394.0) | 338.0 (282.8–453.5) | 308.0 (217.0–359.5) | 0.05 | |
| IGF-I (SDS) | 95 | 2.8 (1.5) | 2.9 (1.5) | 2.8 (1.5) | 0.67 | |
| IGFBP-3 (ng/mL) | 95 | 4555 (4055–5082) | 4600 (4207–5275) | 4475 (3975–5000) | 0.13 | |
| IGFBP-3 (SDS) | 95 | 1.25 (0.65–1.86) | 1.17 (0.79–1.94) | 1.30 (0.62–1.86) | 0.77 | |
| IGFBP-1 (ng/mL) | 95 | 165 (134–220) | 173 (138–216) | 160 (132–234) | 0.83 | |
Data are presented as Mean (SD) or median (interquartile range). Comparison between the sexes was analysed by Independent T-test or Mann-Whitney test when appropriate.
| . | . | . | . | . | P value . | |
|---|---|---|---|---|---|---|
| . | . | All children (N = 101) . | Female (N = 40) . | Male (N = 61) . | Mann-Whitney . | T-test . |
| Baseline | N | |||||
| Age (years) | 101 | 6.2 (1.7) | 5.8 (1.3) | 6.5 (1.8) | 0.06 | |
| Weight (SDS) | 101 | -3.2 (1.0) | -3.2 (1.0) | -3.1 (1.1) | 0.30 | |
| Height (SDS) | 101 | -3.4 (0.8) | -3.5 (0.9) | -3.4 (0.7) | 0.27 | |
| Bioactive IGF-I (µg/L) | 94 | 1.6 (0.7) | 1.8 (0.7) | 1.5 (0.6) | 0.03 | |
| Bioactive IGF-I (SDS) | 94 | -1.2 (1.8) | -0.5 (1.6) | -1.6 (1.8) | 0.005 | |
| IGF-I (ng/mL) | 95 | 81.9 (62.1–111.0) | 91.5 (65.0–118.8) | 79.0 (57.2–110.0) | 0.25 | |
| IGF-I (SDS) | 95 | -1.2 (1.2) | -1.2 (1.1) | -1.1 (1.3) | 0.87 | |
| IGFBP-3 (ng/mL) | 95 | 2870 (2380–3475) | 2870 (2580–3560) | 2780 (2235–3467) | 0.23 | |
| IGFBP-3 (SDS) | 95 | -0.92 (-1.5 to -0.01) | -0.92 (-1.37-0.12) | -0.93 (-1.73 to -0.04) | 0.53 | |
| IGFBP-1 (ng/mL) | 95 | 239 (174–320) | 258 (179–350) | 233 (171–294) | 0.27 | |
| After 1 year of GH therapy | ||||||
| Age (years) | 99 | 7.3 (1.6) | 6.9 (1.4) | 7.5 (1.7) | 0.10 | |
| Weight (SDS) | 96 | -2.2 (1.0) | -2.2 (0.9) | -2.1 (1.2) | 0.70 | |
| Height (SDS) | 99 | -2.4 (0.8) | -2.5 (0.9) | -2.4 (0.8) | 0.58 | |
| Bioactive IGF-I (µg/L) 1 year | 94 | 2.9 (0.9) | 3.0 (0.9) | 2.9 (0.9) | 0.60 | |
| Bioactive IGF-I (SDS) 1 year | 94 | 1.1 (1.4) | 1.1 (1.0) | 1.1 (1.6) | 0.99 | |
| IGF-I (ng/mL) | 95 | 312.0 (225.0–394.0) | 338.0 (282.8–453.5) | 308.0 (217.0–359.5) | 0.05 | |
| IGF-I (SDS) | 95 | 2.8 (1.5) | 2.9 (1.5) | 2.8 (1.5) | 0.67 | |
| IGFBP-3 (ng/mL) | 95 | 4555 (4055–5082) | 4600 (4207–5275) | 4475 (3975–5000) | 0.13 | |
| IGFBP-3 (SDS) | 95 | 1.25 (0.65–1.86) | 1.17 (0.79–1.94) | 1.30 (0.62–1.86) | 0.77 | |
| IGFBP-1 (ng/mL) | 95 | 165 (134–220) | 173 (138–216) | 160 (132–234) | 0.83 | |
| . | . | . | . | . | P value . | |
|---|---|---|---|---|---|---|
| . | . | All children (N = 101) . | Female (N = 40) . | Male (N = 61) . | Mann-Whitney . | T-test . |
| Baseline | N | |||||
| Age (years) | 101 | 6.2 (1.7) | 5.8 (1.3) | 6.5 (1.8) | 0.06 | |
| Weight (SDS) | 101 | -3.2 (1.0) | -3.2 (1.0) | -3.1 (1.1) | 0.30 | |
| Height (SDS) | 101 | -3.4 (0.8) | -3.5 (0.9) | -3.4 (0.7) | 0.27 | |
| Bioactive IGF-I (µg/L) | 94 | 1.6 (0.7) | 1.8 (0.7) | 1.5 (0.6) | 0.03 | |
| Bioactive IGF-I (SDS) | 94 | -1.2 (1.8) | -0.5 (1.6) | -1.6 (1.8) | 0.005 | |
| IGF-I (ng/mL) | 95 | 81.9 (62.1–111.0) | 91.5 (65.0–118.8) | 79.0 (57.2–110.0) | 0.25 | |
| IGF-I (SDS) | 95 | -1.2 (1.2) | -1.2 (1.1) | -1.1 (1.3) | 0.87 | |
| IGFBP-3 (ng/mL) | 95 | 2870 (2380–3475) | 2870 (2580–3560) | 2780 (2235–3467) | 0.23 | |
| IGFBP-3 (SDS) | 95 | -0.92 (-1.5 to -0.01) | -0.92 (-1.37-0.12) | -0.93 (-1.73 to -0.04) | 0.53 | |
| IGFBP-1 (ng/mL) | 95 | 239 (174–320) | 258 (179–350) | 233 (171–294) | 0.27 | |
| After 1 year of GH therapy | ||||||
| Age (years) | 99 | 7.3 (1.6) | 6.9 (1.4) | 7.5 (1.7) | 0.10 | |
| Weight (SDS) | 96 | -2.2 (1.0) | -2.2 (0.9) | -2.1 (1.2) | 0.70 | |
| Height (SDS) | 99 | -2.4 (0.8) | -2.5 (0.9) | -2.4 (0.8) | 0.58 | |
| Bioactive IGF-I (µg/L) 1 year | 94 | 2.9 (0.9) | 3.0 (0.9) | 2.9 (0.9) | 0.60 | |
| Bioactive IGF-I (SDS) 1 year | 94 | 1.1 (1.4) | 1.1 (1.0) | 1.1 (1.6) | 0.99 | |
| IGF-I (ng/mL) | 95 | 312.0 (225.0–394.0) | 338.0 (282.8–453.5) | 308.0 (217.0–359.5) | 0.05 | |
| IGF-I (SDS) | 95 | 2.8 (1.5) | 2.9 (1.5) | 2.8 (1.5) | 0.67 | |
| IGFBP-3 (ng/mL) | 95 | 4555 (4055–5082) | 4600 (4207–5275) | 4475 (3975–5000) | 0.13 | |
| IGFBP-3 (SDS) | 95 | 1.25 (0.65–1.86) | 1.17 (0.79–1.94) | 1.30 (0.62–1.86) | 0.77 | |
| IGFBP-1 (ng/mL) | 95 | 165 (134–220) | 173 (138–216) | 160 (132–234) | 0.83 | |
Data are presented as Mean (SD) or median (interquartile range). Comparison between the sexes was analysed by Independent T-test or Mann-Whitney test when appropriate.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
